Sanofi: authorisation for Kevzara in Europe.
(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals have announced that the European Commission has authorised the marketing of Kevzara (sarilumab), in association with methotrexate (MTX), in the treatment of moderate-to-severe active rhumatoid polyarthritis.
This indication concerns adults who present an inadequate response or intolerance to one or more fundamental anti-rheumatic treatments, such as methotrexate. Kevzara may be given as a mono-therapy in cases of intolerance or contraindication to methotrexate.
This approval follows the go-ahead from the CHMP of the European Medicine Agency (EMA) following à the evaluation of results from seven phase-3 clinical trials of SARIL-RA's clinical development program.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This indication concerns adults who present an inadequate response or intolerance to one or more fundamental anti-rheumatic treatments, such as methotrexate. Kevzara may be given as a mono-therapy in cases of intolerance or contraindication to methotrexate.
This approval follows the go-ahead from the CHMP of the European Medicine Agency (EMA) following à the evaluation of results from seven phase-3 clinical trials of SARIL-RA's clinical development program.
Copyright (c) 2017 CercleFinance.com. All rights reserved.